Sun Pharmaceutical Industries Ltd. - Research Center
524715 SUNPHARMA Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Jun' 24 | Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | |
|---|---|---|---|---|---|
| Sales | 4,498.07 | 5,639.14 | 5,073.75 | 5,096.21 | 4,466.07 |
| Operating profit | 761.07 | 1,893.53 | 1,359.00 | 1,386.32 | 948.76 |
| Interest | 216.08 | 217.59 | 214.92 | 193.63 | 157.94 |
| Gross profit | 627.73 | 1,794.82 | 1,220.88 | 1,299.23 | 954.36 |
| EPS (Rs) | 0.99 | 3.62 | 3.01 | 3.70 | 1.59 |
Quarterly
results in details
| Jun' 24 | Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | |
|---|---|---|---|---|---|
| Other income | 82.74 | 118.88 | 76.80 | 106.54 | 163.54 |
| Stock adjustment | -55.53 | -29.97 | 129.13 | 52.70 | 28.46 |
| Raw material | 973.23 | 1,055.87 | 1,121.64 | 1,066.90 | 1,184.97 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 645.48 | 575.97 | 590.13 | 600.41 | 607.44 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 2,173.82 | 2,143.74 | 1,873.85 | 1,989.88 | 1,696.44 |
| Provisions made | - | - | - | - | - |
| Depreciation | 369.81 | 393.04 | 399.60 | 392.71 | 415.27 |
| Taxation | 20.10 | 534.18 | 30.16 | 17.89 | 9.24 |
| Net profit / loss | 237.82 | 867.60 | 721.31 | 888.63 | 380.64 |
| Extra ordinary item | - | - | -69.81 | - | -149.21 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 239.93 | 239.93 | 239.93 | 239.93 | 239.93 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 16.92 | 33.58 | 26.78 | 27.20 | 21.24 |
| GPM (%) | 13.70 | 31.17 | 23.70 | 24.97 | 20.61 |
| NPM (%) | 5.19 | 15.07 | 14.00 | 17.08 | 8.22 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis